Stockscreener 앱 받기
86.22
0.55%
0.47
시간 외 거래:
85.68
-0.54
-0.63%
전일 마감가:
$85.75
열려 있는:
$85.88
하루 거래량:
252.82K
Relative Volume:
0.60
시가총액:
$3.00B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-23.49
EPS:
-3.67
순현금흐름:
$-74.38M
1주 성능:
+0.69%
1개월 성능:
+30.48%
6개월 성능:
+74.46%
1년 성능:
+92.37%
1일 변동 폭
$84.52
$87.00
1주일 범위
$83.95
$89.79
52주 변동 폭
$30.82
$95.95
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
IRON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
86.22 | 3.21B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Is Disc Medicine Inc. stock trading near support levelsQuarterly Portfolio Report & Real-Time Market Sentiment Reports - newser.com
Applying Wyckoff theory to Disc Medicine Inc. stockJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Why Disc Medicine Inc. stock is considered a top pickWeekly Stock Recap & Low Drawdown Momentum Ideas - newser.com
Morgan Stanley Issues Positive Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine stock reiterated Strong Buy at Raymond James on DISC-0974 potential - Investing.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Disc Medicine to Participate in Upcoming Investor Conferences - Enidnews.com
Disc Medicine (NASDAQ: IRON) to appear at Guggenheim, Stifel, Jefferies; live webcasts - Stock Titan
Can Disc Medicine Inc. stock weather global recession2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Is Disc Medicine Inc. stock in correction or buying zone2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com
Will Disc Medicine Inc. stock maintain growth storyQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What valuation multiples suggest for Disc Medicine Inc. stockEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
WilmerHale Advises Underwriters in $287.5 Million Public Offering of Disc Medicine - WilmerHale
IRON Stock: Morgan Stanley Raises Price Target to $115 | IRON St - GuruFocus
Morgan Stanley Raises Price Target on Disc Medicine to $115 From $90, Keeps Overweight Rating - MarketScreener
Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors - MSN
Chronic Kidney Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Jiangsu HengRui, Disc Medicine, 3SBio, Kind Pharma, Jiangsu Hansoh Pharm - Barchart.com
Disc Medicine (IRON): Evaluating Valuation After New Clinical Trial Plans and FDA Recognition Boost Pipeline Momentum - Yahoo Finance
Disc Medicine planning trial of iron overload treatment for sickle cell - Sickle Cell Disease News
Aug Chart Watch: Why Disc Medicine Inc. stock is considered a top pickQuarterly Earnings Summary & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Top chart patterns to watch in Disc Medicine Inc.July 2025 Breakouts & Consistent Profit Focused Trading Strategies - newser.com
How Disc Medicine Inc. stock performs in interest rate cycles2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment - TipRanks
Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera - TipRanks
Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease - TipRanks
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? - sharewise.com
Disc Medicine’s Promising EPP Treatment Study: Key Updates and Market Impact - TipRanks
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):